Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Björkhem-Bergman L et al. | Effect of Statin Treatment on Plasma 4β-Hydroxycholesterol Concentrations. | 2016 | Basic Clin. Pharmacol. Toxicol. | pmid:26617265 |
Gjestad C et al. | 4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation? | 2016 | Br J Clin Pharmacol | pmid:26574235 |
Woolsey SJ et al. | Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects. | 2016 | Basic Clin. Pharmacol. Toxicol. | pmid:26399557 |
Pataj Z et al. | Quantification of oxysterols in human plasma and red blood cells by liquid chromatography high-resolution tandem mass spectrometry. | 2016 | J Chromatogr A | pmid:26607314 |
Vanhove T et al. | Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance. | 2016 | Br J Clin Pharmacol | pmid:27501475 |
Aubry AF et al. | Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity. | 2016 | AAPS J | pmid:27350147 |
Ishida T et al. | Relationship between the plasma fentanyl and serum 4β-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain. | 2016 | Drug Metab. Pharmacokinet. | pmid:27236640 |
Xue YJ et al. | Use of 4β-hydroxycholesterol in animal and human plasma samples as a biomarker for CYP3A induction. | 2016 | Bioanalysis | pmid:26805594 |
de Graan AJ et al. | 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. | 2015 | Br J Clin Pharmacol | pmid:26119961 |
Naito T et al. | CYP3A activity based on plasma 4β-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine. | 2015 | Drug Metab. Pharmacokinet. | pmid:26654672 |